JWG-045
JWG-045 is a selective ERK5 inhibitor. JWG-045 exhibits unique ferroptosis-resistant activity independent of ERK5 inhibition. JWG-045 can be used in breast cancer research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1234480-61-5
- Fòrmula: C27H33N7O2
- Peso molecular:487.60
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
ERK5 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
0.23 μM
Compound: 24
|
Inhibition of EGF-induced BMK1 autophosphorylation in human HeLa cells by SDS-PAGE analysis
Inhibition of EGF-induced BMK1 autophosphorylation in human HeLa cells by SDS-PAGE analysis
|
[PMID: 21412406] |
JWG-045 (3 μM; 24 h) reduces cell density modestly in BT474 cells and protects both BT474 and MDA-MB-231 breast cancer cells from RSL3-induced ferroptotic cell death[1].
JWG-045 (3 μM; 24 h) protects ERK5-silenced MDA-MB-231 triple-negative breast cancer cells from RSL3-induced ferroptosis independently of ERK5 expression[1].
JWG-045 (3 μM; 6 days) reduces cell density in Trastuzumab (HY-P9907)-resistant BT474 breast cancer cells and restores sensitivity to Trastuzumab[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BT474 luminal B breast cancer cells, MDA-MB-231 triple-negative breast cancer cells
-
Concentration:3 μM (single treatment; pre-incubated then combined with RSL3)
-
Incubation Time:24 h (single treatment; total incubation with RSL3); 20 h (live-cell imaging)
-
Result:Caused a modest, statistically significant reduction in BT474 cell density.
Reduced RSL3-induced cytotoxicity in both BT474 and MDA-MB-231 cells, significantly increasing cell density compared to RSL3 alone.
Prevented the time-dependent decrease in BT474 cell confluency induced by RSL3 over 20 hours.
-
Cell Line:ERK5-silenced MDA-MB-231 triple-negative breast cancer cells
-
Concentration:3 μM (alone; combined with RSL3)
-
Incubation Time:24 h
-
Result:Blocked RSL3-induced ferroptotic death in both control and ERK5-silenced MDA-MB-231 cells, significantly increasing cell density compared to RSL3 alone.
-
Cell Line:Trastuzumab-resistant BT474 breast cancer cells
-
Concentration:3 μM (alone; combined with Trastuzumab)
-
Incubation Time:6 days
-
Result:Reduced BT474 cell density.
Restored the growth inhibitory effect of trastuzumab in Trastuzumab-resistant BT474 cells to the level achieved by Trastuzumab monotherapy in parental BT474 cells.
Chemical Information
-
No. CAS 1234480-61-5
-
Peso molecular 487.60
-
Fòrmula C27H33N7O2
-
SMILES
O=C(N(C1=CN=C(N=C12)NC3=CC=C(C=C3OC)N4CCN(CC4)C)C)C5=CC=CC=C5N2C(C)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JWG-045 Related Classifications
HY-181968 Related Classifications
Powered by Bioz